Apellis(APLS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $200 million, and for the full year 2025, it was $1 billion, which included a one-time $275 million upfront payment from the Sobi royalty repurchase agreement [20] - Syfovre net product revenue for Q4 was $155 million and $587 million for the full year 2025, with total injections growing approximately 17% year-over-year despite a modest decline in revenue due to elevated use of free goods [11][20] - Empaveli reported U.S. net product revenue of $35 million for Q4 and $102 million for the full year 2025, with a market penetration of over 5% after its first full quarter [22][9] Business Line Data and Key Metrics Changes - Syfovre continues to lead the geographic atrophy (GA) market, with strong physician and patient demand, and is expected to remain a stable revenue stream through 2026 [7][11] - Empaveli's launch trajectory is progressing well, with strong early market receptivity and a growing patient pipeline, particularly in C3G and primary IC-MPGN [8][12] - The company is advancing pivotal trials in nephrology for focal segmental glomerulosclerosis and delayed graft function, expanding the Empaveli franchise [10][18] Market Data and Key Metrics Changes - The company expects to strengthen Syfovre's leadership in geographic atrophy and drive growth with Empaveli across rare kidney diseases [7] - Empaveli's strong efficacy and safety profile are driving adoption, with expectations that it could ultimately be used by up to 50% of the estimated 5,000 U.S. patient population for C3G and primary IC-MPGN [9][15] Company Strategy and Development Direction - The company is focused on three strategic pillars: strengthening Syfovre's leadership, driving growth with Empaveli, and advancing an innovative pipeline [7] - The introduction of a best-in-class prefilled syringe and an AI-enabled approach for Syfovre is aimed at improving treatment accessibility and workflow efficiency [8][10] - The company aims to self-fund its pipeline and drive long-term value through disciplined financial execution [10][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term value creation potential of the company, emphasizing a strong balance sheet and disciplined execution [5][25] - The management highlighted the importance of patient access and the evolving dynamics of free goods utilization as third-party programs resume activity [21][57] - The company anticipates modest inventory reduction in Q1 2026 alongside typical seasonal dynamics, with a focus on maintaining a stable net price through the year [21][64] Other Important Information - The company ended 2025 with $466 million in cash and cash equivalents, providing substantial flexibility to fund operations [23] - A $25 million milestone payment was triggered by Sobi's European Commission approval for Aspaveli in C3G and primary IC-MPGN [23] Q&A Session Summary Question: Empaveli launch and growth potential - Management noted that Empaveli is on a clear path to blockbuster status, with a focus on broadening accounts and improving patient identification [29][30] Question: Syfovre five-year data significance - The five-year GALE data shows significant benefits in delaying progression of geographic atrophy, which may lead to earlier treatment for patients [34][36] Question: Empaveli penetration timeline - Management expects a steady ramp in penetration, with a focus on pediatric and post-transplant patients as key growth areas [39][40] Question: Prefilled syringe impact - The prefilled syringe is expected to enhance practice efficiency and support broader adoption of Syfovre [50][52] Question: Free goods dynamics - Management emphasized the commitment to patient access through free goods, which may impact new patient onboarding [97][98]